Financial incentives can reinforce consumer behavior (for example, offering money back for using a specific credit card), and these procedures are gaining traction to modify health behaviors. Patel and colleagues' study examining the efficacy of incentives to reinforce walking 7000 steps daily (1) is commendable, and the results underscore the complex nature of these interventions and the behaviors that they are designed to influence. Reinforcement interventions are grounded in not only behavioral economics but also behavior analysis, which relies heavily on principles of operant conditioning. For example, reinforcing successive approximations toward the goal behavior (that is, shaping) typically works best.
authors' assertions of accuracy. Several issues cast doubt here, not the least of which concerns smartphone placement (that is, a person's step counts can vary depending on where the smartphone is carried, such as in a pocket or purse) (3, 4) . The authors concede that the continuous outcome of steps per day had a wider distribution than expected, which made detecting group differences difficult. This factor is a serious limitation, especially considering the binary nature of the primary study outcome (achieving more or less than 7000 steps per day). Many participant-days may have been inaccurately categorized as the goal having been met or not because of measurement issues rather than true patterns of physical activity.
Finally, none of the interventions drove physical activity when incentives were no longer offered. In future work, focusing less on the short-term magnitude of effect and more on the quality of the behavior change may be appropriate-that is, more on the effect on behaviors after the incentive is stopped and on intrinsic motivation, a key predictor of sustained change in health behavior. IN RESPONSE: Drs. Weinstock and Petry note that behavior change is complex and reinforcement is an important component of interventions to increase physical activity. Although we agree with these comments, our study focused on the effect of different ways to frame financial incentives. Our findings show that, holding reinforcement constant, financial incentives framed as a loss were most effective. A prior study by Drs. Weinstock and Petry revealed important insights but should be compared with our study with caution, because theirs was smaller, did not target overweight and obese adults, used a different step goal, and had a different primary outcome measure (1) .
Drs. Mitchell and Oh question the appropriateness of the same 7000-step goal for different participants. We agree that persons may vary in their baseline activity level; however, we noted as a limitation that baseline data were not available. We also provided several reasons supporting a 7000-step goal, including its endorsement by the American College of Sports Medicine (2) . Many prior studies have used a 10 000-step goal; however, this target has been shown to disengage more sedentary persons who could benefit the most from these types of interventions (3) .
Drs. Mitchell and Oh also state that tracking step counts will vary on the basis of how a device is carried. We agree, but this statement is true for any device, not just smartphones. In addition, our prior work found that smartphones varied less in tracking step counts than wearable devices (4) . Drs. Mitchell and Oh also comment that the control group may have increased their activity because of the participation incentive. Although this could be true, the same participation incentive was used for all study groups; therefore, we were able to evaluate the differential effect of the intervention incentives, which was our primary goal. We agree that more research is needed to evaluate how to sustain behavior change for longer periods.
These comments highlight that behavior change is hard and driven by many factors. However, our findings show that insights from behavioral economics can improve the effectiveness of financial incentive-based interventions for physical activity. 
Mitesh S. Patel, MD, MBA, MS

IN RESPONSE:
We appreciate Dr. Cain and Ms. Goldstone's concern about the possibility of falsely low serum creatinine measurements in the presence of NAC when the Trinder and Trinder-like reaction assays are used. When we reviewed Genzen and associates' study (1), we found that low doses of NAC did not substantially affect the serum creatinine level. Thus, we see no reason to change our conclusion that low strength of evidence indicates that low-dose NAC plus intravenous saline compared with intravenous saline had a clinically important benefit.
The concern then mainly applies to studies using high doses of NAC. Many of the studies included in our review used high doses of this agent, which we defined as more than 1200 mg/d. Several may have used doses high enough to cause a small effect on the creatinine level if measured by the Trinder assay. Unfortunately, few studies reported which assay was used to measure the serum creatinine levels. None reported using the Trinder assay.
We cannot exclude the possibility that use of the Trinder assay contributed to a small overestimation of the effect of high-dose NAC, but that would not explain why we did not find a clinically important benefit for high-dose NAC with intravenous saline compared with intravenous saline alone. Although we stand by our conclusions about the effects of NAC on contrast-induced nephropathy, we agree that studies of this agent to prevent nephrotoxicity should be more consistent in reporting the assay used to measure serum creatinine levels. Hematuria as a Marker of Occult Urinary Tract Cancer TO THE EDITOR: Although I applaud Nielsen and Qaseem for promoting guidelines for the management of patients with hematuria (1), I believe that their advice needs to be more nuanced for those with microscopic, rather than gross, hematuria. Occult cancer may be the most serious concern in patients with gross hematuria; however, glomerular disease with its attendant risks for chronic kidney disease and premature death is a serious condition in those with microscopic hematuria, particularly when affected patients present in the primary care setting and are not referred to specialty clinics. A careful urinary sediment examination looking for either erythrocyte casts or greater than 5% acanthocytes, which have almost 100% specificity for glomerular disease (2) (3) (4) , is a noninvasive way to spare patients from unnecessary imaging or cystoscopy. So, rather than a mere peripheral mention in Figure 1 of the guideline, examination of the morphologic characteristics of erythrocytes should be added to High-Value Care Advice 3, "Clinicians should confirm heme-positive results of dipstick testing with microscopic urinalysis that demonstrates 3 or more erythrocytes per high-powered field before initiating further evaluation in all asymptomatic adults."
Eric
High-Value Care Advice 5, "Clinicians should consider urology referral for cystoscopy and imaging in adults with microscopically confirmed hematuria in the absence of some demonstrable benign cause," is unbalanced. It suggests that urology referral is needed for cystoscopy and imaging. I contend that many physicians feel competent to consider whether ultrasonography, computed tomography scanning, or magnetic resonance imaging is appropriate and that such imaging should almost always precede cystoscopy. IN RESPONSE: Dr. Brown's first point addressing cases where the clinical presentation suggests glomerular sources is welltaken. As we discussed, current guidelines differ in their recommendations for evaluation of patients with hematuria who have findings suggestive of potential nephrologic disorders, such as hypertension, renal insufficiency, cellular casts, proteinuria, or dysmorphic erythrocytes. The American Urological Association and British Association of Urological Surgeons recommend concurrent nephrologic and urologic evaluation in this context, whereas the Canadian and Dutch guidelines suggest referral to a nephrologist as an alternative starting point. We also noted in the Limitations of the Evidence section that such presentations logically suggest nephrology consultation as the appropriate first and potentially only consult but that a detailed examination of practice in that context was beyond the scope of our guideline. We appreciate that Dr. Brown has provided excellent references to support the suggested approach.
As for his second point about High-Value Care Advice 5, urology referral is, in our experience, needed for cystoscopy. The recommendation for cystoscopy in the evaluation of hematuria as a marker of occult urinary tract cancer was consistent across the guidelines that we reviewed (Table 1 in our guideline) and with the fact that bladder cancer is the most common cancer discovered when evaluating patients with this finding. We found no evidence to support noninvasive imaging alone as an adequate diagnostic evaluation to exclude bladder cancer. Nevertheless, we share Dr. Brown's concern that limited evidence supports the recommendation for cystoscopy in patients with microhematuria who are younger than 40 years and have no risk factors for bladder cancer.
Uncertainty around criteria for referral-as well as uncertainty about which, if any, method of upper urinary tract imaging is indicated for a given patient-represents unmet needs frustrating the goal of high-value care for this common clinical presentation. (1) conclusions on Sihvonen and colleagues' placebo-controlled trial. The results of this trial do not support a role for arthroscopic partial meniscectomy (APM) in patients with symptomatic degenerative meniscal tears (2, 3). Katz and Jones state that, on the basis of the available evidence, physical therapy and APM both have a role in this clinical population. However, they neglect to note that the open, randomized trials that have compared APM with physical therapy probably overestimated any benefit of surgery because of bias inherent in unblinded trials, whereas no between-group differences in outcomes were observed for up to 2 years in the single open trial without substantive crossover (4). The results of these studies are entirely in keeping with Sihvonen and colleagues' conclusions (2, 3) . Further, Katz and Jones did not mention the potential long-term harms of APM-such as earlier progression to joint replacement-particularly in older persons (5) . We are also unaware of any randomized, controlled trials that have investigated the efficacy of supervised exercise or physical therapy compared with placebo or watchful waiting for this population; therefore, the true efficacy of this treatment method for symptomatic degenerative meniscal tears remains unknown.
Matthew Nielsen, MD, MS
We take particular issue with the conclusion that APM should be offered to patients whose condition does not respond to nonoperative treatment, namely, physical therapy. The least-biased evidence shows that APM is no more effective than placebo in patients with proven meniscus tears, regardless of mechanical symptoms. The failure of physical therapy does not alter the (lack of) effectiveness of APM.
We contend that the more we learn, the more we do know. The role of APM has become clearer because of Sihvonen and colleagues' studies. This therapy should not be offered to patients with degenerative meniscus tears, regardless of their preference (which relies on the information available to them) and of the success or failure of any other treatment.
IN RESPONSE:
We agree, in general, with Drs. Buchbinder and Harris' critical assessment on the efficacy of APM in patients with degenerative meniscal tear. However, we would like to comment on 2 arguments that they make in support of their concluding statement that APM should not be offered to patients with degenerative meniscal tear.
First, although APM is a risk factor for osteoarthritis progression, meniscal damage is a risk factor, as well (1) . No studies to date have disentangled the effect of surgery from the effect of the underlying tear. At this point, advising a patient with meniscal tear that surgery increases the risk for osteoarthritis progression would not be appropriate.
Second, we agree that Yim and associates' results do not offer support for surgery (2) . And we, too, are impressed with Sihvonen and colleagues' findings that both APM and sham groups improved considerably after surgery with no difference between groups in this well-designed and well-executed trial (3) . However, in their brief summary of APM trials, Drs. Buchbinder and Harris did not include Gauffin and coworkers' trial, which reported that middle-aged participants with degenerative meniscal tear randomly assigned to physical therapy plus surgery had considerably greater pain relief than those randomly assigned to physical therapy without surgery (4) . The between-group difference was 10.6 points (95% CI, 3.4 to 18.0 points) on the Knee Injury and Osteoarthritis Outcome Score pain scale. In addition, the MeTeOR (Meniscal Tear in Osteoarthritis Research) trial reported that participants who crossed over to APM improved substantially after surgery (5) .
Taken together, this matrix of trial evidence is rich, fascinating, and somewhat contradictory. It certainly does not provide strong support for APM in patients with degenerative meniscal tear. But with 1 well-done trial finding unequivocal benefit for APM (4), we are uncomfortable dismissing surgery altogether.
Jeffrey N. Katz Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality TO THE EDITOR: Padwal and colleagues' analysis of body fat percentage, body mass index (BMI), and all-cause mortality (1) was interesting in terms of addressing the uncertainty surrounding traditionally used anthropometric measurements represented by BMI. Their study must be robust given its large population and long duration; furthermore, although it was done retrospectively, there could be no better design to examine the question being evaluated. However, I question the interpretation and expression of this study's results.
The authors state that mortality increased as BMI decreased and body fat percentage increased, showing figures for hazard ratios for death according to the changes in these variables. In Tables 2 and 3 , mortality significantly increased in only the lowest BMI quintile (<22.52 kg/m 2 ) and the highest quintile of body fat percentage (>36.14%). In all other quintiles, mortality did not significantly differ. This increase did not indicate progressive trends, considering the insignificant results in other quintiles.
The figures depicting hazard ratios used a different range for BMI and mean body fat. As such, they seem exaggerated and could lead to misperception rather than a precise interpretation of the results described in those tables. This study used a classification for BMI that differed from that of the World Health Organization, but the authors did not clearly note why these narrowly divided quintiles were used. When they were applied, the figures would be expected to show changes among those narrow ranges rather than the wide ranges of outliers.
Finally, men had a greater change in mortality than women in this study. Including cause-specific mortality would reveal important information in line with obesity evaluation. IN RESPONSE: When we summarized the relationships between mortality and BMI and mortality and body fat percentage, we were describing general trends apparent in the fully adjusted results presented in the article's Table 3 and Figure  2 . Although it is true that not all quintiles were statistically significant, progressive trends are apparent in these results. We explicitly point out the significant results in the text of the Results section, and all CIs were provided in Table 3 .
Dong Hoon Lee, MD
Quintile-based analysis is a commonly used method to examine relationships among anthropometric indices and mortality and was our primary analysis chosen a priori. Appendix Table 2 of our article also provided an analysis based on World Health Organization thresholds that was consistent with the quintile-based analysis.
We agree that cause-specific mortality would have been interesting; however, we did not have access to these data. (2) with the Dietary Guidelines for Americans (DGAs) (3). The DGAC report was developed by 14 experts who reviewed and summarized peer-reviewed evidence on diet and health. It served as the scientific basis for the federal government to develop the DGAs, policy documents subject to strong congressional and industry influences. The DGAs were written by federal staff without involvement of the DGAC. Therefore, Nissen's question, "How can the same committee arrive at diametrically opposite conclusions?," should not even be a question. The DGAC report did not retain the previous upper limit for dietary cholesterol of 300 mg/d on the basis of the weak relationship between dietary cholesterol and serum cholesterol levels. The DGAs followed the recommendation of the DGAC and emphasized that a healthy dietary pattern, such as a Mediterranean-type diet, is typically low in saturated fat and dietary cholesterol.
Raj Padwal, MD, MSc Sumit R. Majumdar, MD, MPH
The PREDIMED (Prevenció n con Dieta Mediterrá nea) trial was built on prior observational evidence from both ecological and prospective cohort data (for example, the Nurses' Health Study and other large cohorts) that supported benefits of the Mediterranean diet (4). In the DGAC report, PREDIMED, along with consistent evidence from large cohort studies, was extensively cited to recommend a Mediterranean-style diet as one of several healthy eating patterns.
Nissen's assertion that evidence does not support limitation of saturated fat is unfounded. The DGAC reviewed extensive evidence from 7 recent systematic reviews or metaanalyses, including the controversial meta-analysis cited by Nissen (5) . On the basis of evidence from both randomized, controlled trials and large cohort studies, the committee concluded that replacing saturated fat with polyunsaturated fat significantly reduces low-density lipoprotein cholesterol levels and risk for cardiovascular disease but that replacing saturated fat with overall carbohydrates has few if any benefits. Thus, the DGAs removed the upper limit on total fat and put greater emphasis on specific types of fat.
We are troubled by Nissen's accusation of Dr. Ancel Keys' lack of scientific integrity based on a reporter's controversial popular book. We urge Nissen to offer credible evidence to support his claim. Keys' seminal Seven Countries' Study documented for the first time the huge variation in rates of coronary heart disease among countries, spurring further research to identify the modifiable causes.
Although we agree with Nissen's plea for more National Institutes of Health support for nutritional research-including randomized, controlled trials-we believe that his commentary reflects a misunderstanding of the dietary guidelines process and nutritional science.
TO THE EDITOR:
Nissen (1) is inaccurate in attributing any state of confusion in nutritional knowledge to Ancel Keys. Keys' famous Seven Countries Study, following an ecological design, found a strong correlation (r = 0.84) between mean intake of saturated lipids (as a percentage of total energy intake) and coronary mortality in 16 regions. These results, with the inherent limitations of an ecological design, agree with subsequent stronger evidence and with the U.S. DGAC in limiting saturated lipids (and their main sources, whole-fat dairy and red and processed meats) but not total lipids.
In the Seven Countries Study, the percentage of energy from total lipids had a negligible association with coronary heart disease (2, 3). Keys showed that total cholesterol levels were increased by saturated fatty acid intake but not by total fat intake, stating, "In almost all natural human diets the effect of fat on the serum cholesterol level seems to be dominated by palmitic acid which makes up the bulk of the saturated fatty acid which affects serum cholesterol" (4).
Keys was impressed by the dramatically low rates of heart disease in Crete and other Mediterranean areas despite a high intake of total fat (mainly from olive oil in the 1950s). The low content of saturated lipids could explain this low incidence of coronary heart disease. Keys consequently was also a pioneer in attributing this benefit to a "good Mediterranean diet," and-in stark contrast to Nissen's unsubstantiated affirmations-was anticipatory in observing "low all-causes death rates in populations whose diets were high in total fats with oleic acid dominating the picture" (3). This perceptive and insightful view was later confirmed by large prospective cohort studies with good control of potential confounding; longterm follow-up; and appropriate ascertainment of hard clinical events, including large cohort studies done in Mediterranean areas where high total lipid intake is accompanied by olive oil consumed in great amounts. The hypotheses defended by Keys also agree with the subsequent results of the Lyon Diet Heart study, a randomized clinical trial, and the PREDIMED randomized trial (5) . Therefore, there is consensus and consistency, not controversy, in guidelines that promote a reduction in saturated fat intake but do not establish an upper limit for total lipid intake if it comes from healthy natural vegetable sources, such as olive oil or tree nuts. There is also consensus that the Mediterranean diet is an optimal dietary model for a healthy life. the DGAs and the DGAC scientific report are somehow not linked is simply not credible. The report explicitly states that it is designed to "inform the next edition of the Guidelines." It is correct that the DGAs did not retain the previous cholesterol limit of 300 mg/d; however, at the same time, the report states that "individuals should eat as little dietary cholesterol as possible." This recommendation directly contradicts the guideline recommendation against numerical caps on cholesterol intake.
The authors' impassioned defense of the Seven Countries Study ignores 2 fundamental realities: Correlation does not prove causation, and the country selection for the study was biased. Keys' initial evaluation examined 6 countries, but data were available for 22 countries. These 22 countries included some in which saturated fat consumption is high, such as France, but they were not included (1). The subsequent Seven Countries Study was similarly flawed (2) .
Four meta-analyses, 5 systematic reviews, and 3 nonsystematic reviews have now been published examining clinical trials that found no effect of saturated fats on heart disease, cardiovascular mortality, or total mortality. In some analyses, replacing saturated fats with polyunsaturated vegetable oils reduced some types of cardiovascular events (but not deaths). In 1 analysis looking only at cardiovascular events (again, not deaths), a benefit was seen in replacing saturated fats with polyunsaturated vegetable oils. A summary of these studies is available (3). Other authors have pointed out that guidelines suggesting limitation of dietary fats, including saturated fat, were not evidence-based (4). Neither Dr. Hu and colleagues nor Dr. Martinez-Gonzalez and Ms. Trichopoulou attempt to defend the extreme claims about relationships between food consumption and disease based on observations from the Nurses' Health Study that I pointed out in my article.
As a profession, we can continue to perpetuate the poorquality science that has dominated nutritional research or transition to a new era where dietary evidence is derived from high-quality randomized trials. That was the principal proposition offered by my article. Although these regulations prohibit actual or apparent conflicts of interest, regulatory policy allows waivers to be issued when the participant's expertise is deemed essential to evaluating a specific matter before the advisory committee. The issuance of waivers can be complicated, but the FDA is clear that relevant scientific expertise is a necessary and primary criterion (1) . Therefore, patient and consumer representatives are ineligible to receive waivers for conflicts of interest (1) . In addition, committee members with more than $50 000 in financial relationships are typically ineligible for waivers regardless of expertise.
Steven E. Nissen, MD
During the past decade, financial conflicts of interest in health policy have raised important concerns (2). For example, a growing body of scholarship has documented that some drug manufacturers enlist patient advocacy organizations to influence federal policy (2) (3) (4) .
Objective: To examine financial relationships between drug manufacturers and patient and consumer representatives serving on FDA drug advisory committees.
Methods and Findings:
We examined online FDA archives for data on all 167 advisory committee meetings held between 2009 and 2012. The data identified patient and consumer representatives who participated in each meeting and provided additional information. These data were combined with the results of online research into representatives' backgrounds and employment histories, including their resumes, curricula vitae, social media accounts, and advocacy organization biographies.
We ascertained whether representatives had actual or potential conflicts that were neither waived nor disclosed at the meetings using the FDA's guidelines for determining conflict, which index potential conflicts to the specific matter addressed (5). Patient and consumer representatives participated 315 times during the 167 committee meetings, and we identified 61 conflicts of interest-in other words, conflicts were present 19% of the time (Table) . Ten conflicts resulted from personal relationships between industry and a representative, 28 from a relationship between industry and a patient advocacy organization, 14 from other types of relationships, and 9 from multiple relationships. Seven conflicts involved the manufacturer of the principal drug being discussed during the meeting, 28 involved a direct competitor, and 26 involved a marketplace competitor. Thirty-five conflicts were valued at $50 000 or more, and 1 was valued at less than this amount; assigning a value to the remaining 25 conflicts was not possible. Conflicts occurred at 55 of the 167 meetings, and partic-ipants at 6 meetings had 2 or more conflicts. Finally, 35 of the 55 meetings with conflicts involved values of $50 000 or more.
Discussion: On the basis of these findings, we believe that the FDA should consider changing the way it evaluates conflicts of interest for patient and consumer representatives. We specifically recommend that it revise form 3410. This form directs advisory committee members to list financial relationships between industry and the organizations where representatives serve as officers, including grants awarded to the organizations. However, clarifying directions instruct representatives to consider only grants that are awarded to universities and research institutions. This clarification probably prompts patient and consumer representatives who serve as officers of patient advocacy organizations to ignore the grants section of the disclosure form. This combination induces expression of the ligand for the programmed death-1 cell receptor, which is believed to suppress the immune system and allow the tumor to escape immune control (1) .
S. Scott Graham
Patients with abnormal ALK who are refractory to chemotherapy and agents that are targeted to the tumor's specific characteristics have almost no chance of surviving. Nivolumab is an antibody that blocks ligand activation of the programmed death-1 cell receptor and has produced promising results in refractory Hodgkin lymphoma (2) . That promise suggested its use in ALCL. Patients with ALCL might be amenable to immunologic treatment for other reasons-for example, allogeneic blood stem cell transplantation is especially effective when this lymphoma is in relapse. In addition, an immune response against ALK occurs, the strength of which inversely correlates with risk for relapse (3) .
Objective: To describe the efficacy of nivolumab in a patient with refractory ALK-positive ALCL.
Case Report: A 19-year-old man was diagnosed with NPM-ALK-positive ALCL in June 2014. After 1 course of therapy with a modified cyclophosphamide, daunorubicin, vincristine, and etoposide regimen that included prednisolone, the lymphoma progressed. Real-time, quantitative polymerase chain reaction testing detected a high burden of minimal residual disease, with more than 500 copies of the NPM-ALK gene for every 10 000 copies of the ABL gene (the reference gene) (4) .
We started treatment with brentuximab vedotin, which is an immunotoxin directed against a transmembrane receptor (CD30) that is a member of the tumor necrosis factor superfamily and is upregulated in this cancer. However, the patient developed gastrointestinal bleeding, so we added the ALK inhibitor crizotinib. This combination of drugs led to clinical improvement, but minimal residual disease was still detectable at high levels ( Figure) . After the fourth cycle of brentuximab vedotin, central nervous system progression was diagnosed. Intrathecal therapy and central nervous systemintensified total body irradiation allowed for stem cell transplantation from a matched unrelated donor, after which residual disease was no longer detectable. Four months later, we again found residual disease and restarted crizotinib therapy. The copies of NPM-ALK initially decreased but then rapidly increased. The patient developed a concomitant macrophage activation syndrome, and nodal disease reappeared. Relapse was confirmed by histologic testing that included staining tumor cells to identify the ligand for programmed death-1. Crizotinib therapy was stopped (5) , and a single dose of brentuximab vedotin was poorly tolerated. After the patient gave informed consent, we started treatment with nivolumab, 3 mg/kg of body weight every 2 weeks, on 1 July 2015. The patient rapidly improved clinically with disappearance of the macrophage activation syndrome. After 12 nivolumab infusions, the patient developed grade 2 pneumonitis. We stopped nivolumab treatment, started corticosteroid treatment, and continued this therapy until the clinical symptoms resolved. The patient remained relapse-free and had negative results for residual disease (Figure) without graft-versus-host disease in March 2016, when we last examined him.
Discussion: The initiation of nivolumab therapy in this patient was followed by a sustained and complete remission, even though his ALK-positive ALCL was refractory to chemotherapy and targeted agents and he relapsed after allogeneic stem cell transplantation. This observation further supports the importance of the immune system for controlling this disease. We believe that this finding warrants systematic exploration of programmed death-1 inhibition for treating ALCL.
